UNSPSC 51102833: Chlorcyclizine/hydrocortisone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102833 Chlorcyclizine/hydrocortisone is a Commodity code that in recent state and local procurement activity encompasses pharmaceutical supply through cooperative purchasing contracts and direct buys, though the specific active ingredient has not appeared in recent solicitations. State and local health agencies and county governments are the primary issuing bodies under this code, procuring pharmaceutical products through both piggyback arrangements with established statewide consortia and standalone competitive bids. Scope of work includes supply of pharmaceutical inventory to support public health operations, emergency preparedness, and community health initiatives, with contracts typically structured around annual or multi-year terms with quarterly or periodic delivery schedules.

Recent opportunities show activity in Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (Solicitation Number 26482DPHPREPDB53392) for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets on an Invitation for Bid basis with a 12-month initial term and two one-year renewal options. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026 with a July 26, 2023 response deadline for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, including quarterly delivery to the Seminole County Community Health Building in Sanford, with a two-year initial term and one-year renewal option. Neither solicitation directly addresses the code's stated ingredient, suggesting possible tagging misalignment or limited current demand for this specific pharmaceutical formulation in recent state and local procurement.